Becotatug Vedotin for advanced nasopharyngeal cancer not responding well to initial treatment
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called Becotatug Vedotin for people with locally advanced nasopharyngeal cancer whose tumor did not shrink enough after initial chemotherapy plus immunotherapy. If you qualify, you may receive this targeted therapy to help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- Your cancer must be a type called 'non-keratinizing' nasopharyngeal carcinoma that has not spread to other parts of the body.
- You should have already received 3 cycles of chemotherapy plus immunotherapy, and your tumor did not shrink enough (stable or progressive disease).
- Your overall health should be good enough to be up and about (ECOG 0 or 1).
- Your blood counts, liver function, and kidney function must be within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial studies a drug called MRG003 combined with another therapy that boosts the immune system to fight cancer. It aims to see if this combination can shrink tumors or slow the growth of nasopharyngeal cancer that has returned or spread.
This trial tests a new combination of treatments—a targeted drug that delivers cancer-killing medicine directly to tumor cells, an immunotherapy that helps your immune system fight cancer, and standard chemoradiation—for people with advanced nasopharyngeal cancer. The goal is to see if this combination works better than standard treatment alone.
This study tests whether adding an investigational drug (anlotinib) to standard chemotherapy and radiation, along with immunotherapy, can better control high-risk nasopharyngeal cancer. It aims to see if this combination reduces the chance of the cancer coming back.
This trial tests a new combination of an immunotherapy drug (tislelizumab) plus standard chemoradiotherapy for people with advanced nasopharyngeal carcinoma. It aims to find out if this combination is more effective than standard care alone.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.